Deltaretrovirus particle formation in human and animal viruses
Official title: Deltaretrovirus Morphology and Particle Assembly
Funded at University of Minnesota · NIH-11529246 · Data updated 2026-11-12
This grant studies how deltaretroviruses like HTLV and BLV assemble their particles, with hopes to reveal how these viruses replicate in order to inform future therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | July 15, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $16,223 |
| NIH project number | 3R01GM151775-03S1 |
| Project ID | NIH-11529246 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to a specific patient cohort at this stage; findings could eventually benefit individuals affected by deltaretroviral infections.
✕Less likely to help
There may be no immediate benefit for patients during the initial basic science phase.
What this research studies
If funded, researchers at the University of Minnesota will investigate the steps by which deltaretroviruses assemble and mature, including how the core Gag and capsid proteins come together at the cell membrane. They will use cell culture systems to observe immature and mature virus particles and compare them to other retroviruses such as HIV. The goal is to identify new details about particle formation that could point to targets for therapies or vaccines in the future. This work could lay groundwork for improved understanding of virus biology that could eventually lead to better prevention and treatment options for associated leukemias.
Why it matters
Potential benefit: Gaining insights into deltaretrovirus assembly could inform future strategies to prevent or disrupt viral replication in diseases like HTLV and BLV.
How similar studies have gone: Preliminary work shows distinct particle formation pathways for deltaretroviruses, suggesting this is a promising but specialized area.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Mansky, Louis M — University of Minnesota
- Study coordinator: Mansky, Louis M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.